We are international

Exciting News for Relapsed and Refractory Multiple Myeloma Patients!

| No Comments | No TrackBacks

This morning the very much awaited for announcement was made:  the FDA has granted Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma.  The article is below.  What this means for patients and their caregivers is new hope.  While myeloma is not yet curable, it is treatable, and with each new drug that is approved, patients are able to choose wisely with their doctors which treatment may be the best option for them.  Each new drug buys us time and the possibility of longer remissions and better quality of life . . . until someday there is a cure!

Links that may be of interest to you:
Enhanced by Zemanta

Leave a comment

To subscribe to this blog, enter your email address below:

  • Connecticut Multiple Myeloma Fighters
  • Michael's Myeloma Bio
  • Michael Performs: "I'm Not Leavin'"
  • About Robin

  • Caregivers' Journal

    All Blogs

    IMF Articles